Kronos is set to reduce its workforce by approximately 83% by year-end as it seeks ways to remain viable, which may involve potential business combinations or selling off its remaining preclinical assets, as stated in a release on Wednesday.
As of March 11, the organization had a workforce of 62 full-time employees, as stated in its yearly SEC report.
Following Kronos Bio’s recent choice to discontinue its final clinical asset, the company announced plans to implement “significant expense reduction strategies” to extend its runway. Currently, one element of the beleaguered biotech’s efforts to reduce expenses is becoming clearer.
The most recent wave of layoffs at the organization comes after two previous rounds of workforce reductions revealed since November of the prior year. The recent changes also extend to the upper management at Kronos, reflecting the trend seen in earlier reductions.
The president and CEO of the biotech company, Norbert Bischofberger, Ph.D., will be resigning from his position on December 3. Kronos stated that he will stay on the board and will continue to be accessible to the company in an advisory role.